Epigenetic Reprogramming in Cancer
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The demonstration of induced pluripotency and direct lineage conversion has led to remarkable insights regarding the roles of transcription factors and chromatin regulators in mediating cell state transitions. Beyond its considerable implications for regenerative medicine, this body of work is highly relevant to multiple stages of oncogenesis, from the initial cellular transformation to the hierarchical organization of established malignancies. Here, we review conceptual parallels between the respective biological phenomena, highlighting important interrelationships among transcription factors, chromatin regulators, and preexisting epigenetic states. The shared mechanisms provide insights into oncogenic transformation, tumor heterogeneity, and cancer stem cell models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [117]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Expression of a single transfected cDNA converts fibroblasts to myoblasts
Davis, R. L., Weintraub, H., & Lassar, A. B. (1987) · Cell · doi:10.1016/0092-8674(87)90585-x · Cited by 3,385
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Cited by
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
“3 or its chaperone proteins that promote telomerase-independent telomere lengthening (57, 94), or by nongenetic mechanisms that simulate self-renewing stem cell states (9, 95).”
BackgroundSelf-citationThe emerging roles of circRNAs in cancer and oncology
Kristensen, L. S., Jakobsen, T., Hager, H., & Kjems, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00585-y · Cited by 1,256
Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma
Tirosh, I., Venteicher, A. S., Hebert, C., Escalante, L. E., Patel, A. P., Yizhak, K., Fisher, J. M., Rodman, C., Mount, C., Filbin, M. G., et al. (2016) · Nature · doi:10.1038/nature20123 · Cited by 1,234
Self-citationSever, R., & Brugge, J. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006098 · Cited by 989
“Changes in the methylation state of promoters of genes that impact cancer can also play an important role in oncogenesis (Sandoval and Esteller 2012; Suva et al. 2013).”
Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells
Suvà, M. L., Rheinbay, E., Gillespie, S. M., Patel, A. P., Wakimoto, H., Rabkin, S. D., Riggi, N., Chi, A. S., Cahill, D. P., Nahed, B. V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.030 · Cited by 944
“…point to the importance of understanding the epigenetic identities and susceptibilities of such aggressive subpopulations (Binda et al., 2012; Day et al., 2013; Friedmann-Morvinski et al., 2012; Kim et al., 2013; Piccirillo et al., 2006; Singh et al., 2004; Son et al., 2009; Suva et al., 2013).”
Self-citationEpigenetic modulators, modifiers and mediators in cancer aetiology and progression
Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.13 · Cited by 841
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Tumor metastasis: moving new biological insights into the clinic
Wan, L., Pantel, K., & Kang, Y. (2013) · Nature Medicine · doi:10.1038/nm.3391 · Cited by 748
Hou, Y., Guo, H., Cao, C., Li, X., Hu, B., Zhu, P., Wu, X., Wen, L., Tang, F., Huang, Y., et al. (2016) · Cell Research · doi:10.1038/cr.2016.23 · Cited by 647
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
Timp, W., & Feinberg, A. P. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3486 · Cited by 586
The evolving metabolic landscape of chromatin biology and epigenetics
Dai, Z., Ramesh, V., & Locasale, J. W. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0270-8 · Cited by 494
Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7683 · Cited by 489
Dedifferentiation and reprogramming: origins of cancer stem cells
Friedmann‐Morvinski, D., & Verma, I. M. (2014) · EMBO reports · doi:10.1002/embr.201338254 · Cited by 495
“There are also several examples of CRs involved in active chromatin states that play important roles both in reprogramming and in cancer (e.g., MLL and Dot1l [60]).”
DNA methylation: An epigenetic mark of cellular memory
Kim, M., & Costello, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.10 · Cited by 450
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Mutational landscape of intrahepatic cholangiocarcinoma
Zou, S., Li, J., Zhou, H., Frech, C., Jiang, X., Chu, J. S. C., Zhao, X., Li, Y., Li, Q., Wang, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6696 · Cited by 434
“Oxidative phosphorylation (37) Epigenetic regulator (52) TGF-β/SMAD4 signalling (17) Ras/PI3K signalling (72)”
BackgroundABC Transporters in Cancer Stem Cells: Beyond Chemoresistance
Begicevic, R.-R., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112362 · Cited by 395
“While CSCs and their progeny share the same genotype, they have different epigenetic profiles, resulting in changes to a number of signalling pathways [34,35].”
BackgroundA role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms
Cojoc, M., Mäbert, K., Muders, M. H., & Dubrovska, A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.06.004 · Cited by 393
Chromatin dynamics during cellular reprogramming
Apostolou, E., & Hochedlinger, K. (2013) · Nature · doi:10.1038/nature12749 · Cited by 398
Anticancer drug resistance: An update and perspective
Nussinov, R., Tsai, C.-J., & Jang, H. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100796 · Cited by 386
DNA methyltransferases and their roles in tumorigenesis
Zhang, W., & Xu, J. (2017) · Biomarker Research · doi:10.1186/s40364-017-0081-z · Cited by 382
Sex differences in cancer mechanisms
Rubin, J. B., Lagas, J. S., Broestl, L., Sponagel, J., Rockwell, N., Rhee, G., Rosen, S. F., Chen, S., Klein, R. S., Imoukhuede, P., et al. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00291-x · Cited by 366
Riggi, N., Suvà, M. L., & Stamenkovic, I. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2028910 · Cited by 344
Self-citationThe ID proteins: master regulators of cancer stem cells and tumour aggressiveness
Lasorella, A., Benezra, R., & Iavarone, A. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3638 · Cited by 355
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Saghafinia, S., Mina, M., Riggi, N., Hanahan, D., & Ciriello, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.082 · Cited by 357
“DMI was significantly associated with mutations of chromatin remodelers, strengthening a link between histone and DNA methylation and suggesting that both need to be considered to understand the impact of recurrent mutations of chromatin remodeling complexes in cancer (Lu and Allis, 2017; Suvà et al., 2013).”
BackgroundSelf-citationIndividualized Medicine from Prewomb to Tomb
Topol, E. J. (2014) · Cell · doi:10.1016/j.cell.2014.02.012 · Cited by 333
“Epigenomic reprogramming has a clear-cut role in cancer, be it via transcription factors or chromatin regulators (Dawson and Kouzarides, 2012; Suvà et al., 2013).”
Mechanisms of cancer resistance in long-lived mammals
Seluanov, A., Gladyshev, V. N., Vijg, J., & Gorbunova, V. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0004-9 · Cited by 323
Scaling by shrinking: empowering single-cell 'omics' with microfluidic devices
Prakadan, S. M., Shalek, A. K., & Weitz, D. A. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.15 · Cited by 325
The Glioma Stem Cell Model in the Era of Single-Cell Genomics
Suvà, M. L., & Tirosh, I. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.001 · Cited by 326
Self-citationDeng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T. (2014) · Gene · doi:10.1016/j.gene.2013.12.019 · Cited by 301
“Cancer is a genetic disease which involves mutational and epigenetic changes which lead to uncontrollable cell proliferation and differentiation (McLeod, 2013; Suva et al., 2013).”
BackgroundProstate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T. M., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 268
Mierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 262
Schulte-Sasse, R., Budach, S., Hnisz, D., & Marsico, A. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00325-y · Cited by 256
Tumor Cell Invasion in Glioblastoma
Vollmann-Zwerenz, A., Leidgens, V., Feliciello, G., Klein, C. A., & Hau, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061932 · Cited by 257
“The phenotype of BTIC is primarily coined by their epigenetic state, and further modified by a number of transcription factors, chromatin regulators and associated cellular networks [44].”
BackgroundCancer stem cell plasticity and tumor hierarchy
Cabrera, M. C. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i1.27 · Cited by 252
Barutcu, A. R., Lajoie, B. R., McCord, R. P., Tye, C. E., Hong, D., Messier, T. L., Browne, G., van Wijnen, A. J., Lian, J. B., Stein, J. L., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0768-0 · Cited by 250
“The development of cancer involves several genetic and epigenetic alterations that result in aberrant gene expression [4–7].”
Sun, Z., Feng, D., Fang, B., Mullican, S. E., You, S.-H., Lim, H.-W., Everett, L. J., Nabel, C. S., Li, Y., Selvakumaran, V., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.10.022 · Cited by 247
“…factors and epigenomic modifiers in carcinogenesis, few mutations have been found in HDACs that are associated with any types of malignancies, even though some HDIs have been approved for treating cancers and many more show similar promise (Garraway and Lander, 2013; Suvà et al., 2013).”
BackgroundCommon stemness regulators of embryonic and cancer stem cells
Hadjimichael, C. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i9.1150 · Cited by 241
Kim, J.-H., Sharma, A., Dhar, S. S., Lee, S.-H., Gu, B., Chan, C.-H., Lin, H.-K., & Lee, M. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1896 · Cited by 248
“The gene encoding the H3K27me3 demethylase UTX often undergoes somatic loss-offunction mutations in multiple cancer types, such as medulloblastoma, renal carcinoma, bladder cancer, leukemia, and prostate tumors [reviewed in (22)].”
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.005 · Cited by 243
“Because KMT2D is mutated in several other types of cancer (Suva et al., 2013) and 2-DG has re-entered clinical trials, our findings may rationalize glycolysis inhibition as an anticancer treatment strategy against other cancer types bearing KMT2D-inactivating mutations besides human KMT2D-inactivated LUAD.”
BackgroundEpigenetic encoding, heritability and plasticity of glioma transcriptional cell states
Chaligne, R., Gaiti, F., Silverbush, D., Schiffman, J. S., Weisman, H. R., Kluegel, L., Gritsch, S., Deochand, S. D., Gonzalez Castro, L. N., Richman, A. R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00927-7 · Cited by 258
Self-citationPRC2 mediated H3K27 methylations in cellular identity and cancer
Conway, E., Healy, E., & Bracken, A. P. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.003 · Cited by 244
Slide-tags enables single-nucleus barcoding for multimodal spatial genomics
Russell, A. J. C., Weir, J. A., Nadaf, N. M., Shabet, M., Kumar, V., Kambhampati, S., Raichur, R., Marrero, G. J., Liu, S., Balderrama, K. S., et al. (2024) · Nature · doi:10.1038/s41586-023-06837-4 · Cited by 225
“Epigenetic dysregulation in cancer facilitates drug resistance and pro-metastatic cell state transitions 36–38 .”
Integrative methods for analyzing big data in precision medicine
Gligorijević, V., Malod‐Dognin, N., & Pržulj, N. (2016) · PROTEOMICS · doi:10.1002/pmic.201500396 · Cited by 216
“Epigenomics findings are cell type-specific and epigenetic re-programming has a clear role in cancer [35,36].”
BackgroundEmerging role of PI3K/AKT in tumor-related epigenetic regulation
Yang, Q., Jiang, W., & Hou, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.04.001 · Cited by 202
Tan, Y., Tajik, A., Chen, J., Jia, Q., Chowdhury, F., Wang, L., Chen, J., Zhang, S., Hong, Y., Yi, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms5619 · Cited by 202
“This explanation is supported by the experimental finding that matrix metalloproteinease (MMP) 14-mediated local softening of the invasive front of mammary epithelial cells is necessary to overcome the stiff elastic resistance of the collagen matrix 44 .”
Cancer cell plasticity: Impact on tumor progression and therapy response
da Silva-Diz, V., Lorenzo-Sanz, L., Bernat-Peguera, A., Lopez-Cerda, M., & Muñoz, P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.009 · Cited by 203
Swierczynski, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2279 · Cited by 198
Allosteric control of mammalian DNA methyltransferases – a new regulatory paradigm
Jeltsch, A., & Jurkowska, R. Z. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw723 · Cited by 203
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Miller, T. E., Liau, B. B., Wallace, L. C., Morton, A. R., Xie, Q., Dixit, D., Factor, D. C., Kim, L. J. Y., Morrow, J. J., Wu, Q., et al. (2017) · Nature · doi:10.1038/nature23000 · Cited by 200
Self-citationBrain tumor stem cells: Molecular characteristics and their impact on therapy
Schonberg, D. L., Lubelski, D., Miller, T. E., & Rich, J. N. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.06.004 · Cited by 198
“P A A uthor M anuscript (Stricker et al., 2013; Suvà et al., 2013).”
BackgroundEGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Liu, F., Hon, G. C., Villa, G. R., Turner, K. M., Ikegami, S., Yang, H., Ye, Z., Li, B., Kuan, S., Lee, A. Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.002 · Cited by 193
“Master transcription factors (TFs) interact with cis-regulatory DNA sequences to control transcriptional repertoires that drive tumor growth and survival (Baylin and Jones, 2011; Suvà et al., 2013).”
The nucleosome remodeling and deacetylase complex in development and disease
Basta, J., & Rauchman, M. (2015) · Translational Research · doi:10.1016/j.trsl.2014.05.003 · Cited by 191
“These therapeutic strategies have the potential to reprogram cells and thereby promote tissue regeneration and repair, and reverse the oncogenic phenotype of tumor cells [for review see [1]].”
KRAS drives immune evasion in a genetic model of pancreatic cancer
Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 191
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2015) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 182
Efficient nanocarriers of siRNA therapeutics for cancer treatment
Subhan, M. A., & Torchilin, V. P. (2019) · Translational Research · doi:10.1016/j.trsl.2019.07.006 · Cited by 183
Merelli, B., Massi, D., Cattaneo, L., & Mandalà, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.002 · Cited by 170
“Cellular transformation and tumor development result rom an accumulation of mutational and epigenetic changes hat alter normal cell growth and survival pathways [1].”
BackgroundZhou, X., Gao, Q., Wang, J., Zhang, X., Liu, K., & Duan, Z. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.033 · Cited by 169
“Furthermore, due to the widespread expression of these core TFs in cancers [13,40,41], linc-RoR could also contribute to cancer formation and lead to new therapies for human cancers.”
BackgroundGenome-scale high-resolution mapping of activating and repressive nucleotides in regulatory regions
Ernst, J., Melnikov, A., Zhang, X., Wang, L., Rogov, P., Mikkelsen, T. S., & Kellis, M. (2016) · Nature Biotechnology · doi:10.1038/nbt.3678 · Cited by 162
“Epigenome maps predict thousands of putative regulatory regions through their in vivo epigenomic signatures 1–8 and are widely used for studying gene regulation 9,10 and disease 11,12 .”
BackgroundStretching the limits: from homeostasis to stem cell plasticity in wound healing and cancer
Ge, Y., & Fuchs, E. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2018.9 · Cited by 168
Single-Cell Transcriptome Analysis Reveals Dynamic Changes in lncRNA Expression during Reprogramming
Kim, D. H., Marinov, G. K., Pepke, S., Singer, Z. S., He, P., Williams, B., Schroth, G. P., Elowitz, M. B., & Wold, B. J. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2014.11.005 · Cited by 164
“Apart from induced pluripotent stem (iPS) cell reprogramming, these defined factors and chromatin regulators have also been shown to facilitate malignant transformation and progression, which might be viewed as a form of pathological reprogramming (Goding et al., 2014; Suva et al., 2013).”
BackgroundHarnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 159
“The reality of accomplishing this, as has been recently stressed (81), is that a similar comprehensive reprogramming occurs during creation of induced pluripotent stem cells from more mature cells (82).”
RNAi screens in mice identify physiological regulators of oncogenic growth
Beronja, S., Janki, P., Heller, E., Lien, W.-H., Keyes, B. E., Oshimori, N., & Fuchs, E. (2013) · Nature · doi:10.1038/nature12464 · Cited by 164
Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles
Pan, J., Ruan, W., Qin, M., Long, Y., Wan, T., Yu, K., Zhai, Y., Wu, C., & Xu, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-19463-2 · Cited by 158
Etchegaray, J., Chávez, L., Huang, Y., Ross, K. N., Choi, J., Martínez-Pastor, B., Walsh, R. M., Sommer, C., Lienhard, M., Gladden, A. D., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3147 · Cited by 171
Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development
Jones, A., Teschendorff, A. E., Li, Q., Hayward, J. D., Kannan, A., Mould, T., West, J., Zikan, M., Cibula, D., Fiegl, H., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001551 · Cited by 152
“Accumulating evidence suggests that the epigenome serves as the interface between the genome and the environment [1,2] and that hypermethylation of stem cell polycomb group target genes (PCGTs—targets for chromatin-modifying complexes that transiently suppress expression and temporarily repress cellular differentiatio…”
BackgroundDelivery strategies and potential targets for siRNA in major cancer types
Lee, S. J., Kim, M. J., Kwon, I. C., & Roberts, T. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.010 · Cited by 154
“Generally, a combination of activatingmutations in so-called oncogenes and the loss of tumor suppressor genes lead to uncontrolled cell growth and blockage of natural apoptotic processes [62,63].”
DAMPs, ageing, and cancer: The ‘DAMP Hypothesis’
Huang, J., Xie, Y., Sun, X., Zeh, H. J., Kang, R., Lotze, M. T., & Tang, D. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.10.004 · Cited by 144
Benítez, J. A., Ma, J., D’Antonio, M., Boyer, A. D., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi‐Jamayran, A., Jameson, N. M., Andersen, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15223 · Cited by 160
Mapping the new molecular landscape: social dimensions of epigenetics
Pickersgill, M., Niewöhner, J., Müller, R., Martin, P., & Cunningham-Burley, S. (2013) · New Genetics and Society · doi:10.1080/14636778.2013.861739 · Cited by 139
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 150
Shaheen, S. Y., Ahmed, M., Lorenzi, F., & Nateri, A. S. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9664-6 · Cited by 140
“Recently, it was also reported that CSCs sub-population exhibit an embryonic stem cell gene expression signature [3, 7].”
BackgroundHistone H3.3 Mutations: A Variant Path to Cancer
Yuen, B. T. K., & Knoepfler, P. S. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.015 · Cited by 134
Powell, C., Grant, A. R., Cornblath, E. J., & Goldman, D. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312009110 · Cited by 144
“Similar epigenetic changes are seen in other cellular reprogramming events such as nuclear transfer (6), heterokaryon formation (7), and carcinogenesis (8).”
BackgroundThe co-evolution of the genome and epigenome in colorectal cancer
Heide, T., Househam, J., Cresswell, G. D., Spiteri, I., Lynn, C., Mossner, M., Kimberley, C., Fernandez-Mateos, J., Chen, B., Zapata, L., et al. (2022) · Nature · doi:10.1038/s41586-022-05202-1 · Cited by 130
“Although we know a lot about the genetic lesions that lead to colorectal malignancies, epigenetic events in colorectal cancer and many other tumour types, despite being recognised as highly significant (Suvà et al., 2013), are severely understudied (Black and McGranahan, 2021).”
Experimental models and tools to tackle glioblastoma
Robertson, F., Marqués‐Torrejón, M. Á., Morrison, G. M., & Pollard, S. M. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.040386 · Cited by 131
“They may be locked into a perpetual cycle of self-renewal (Bulstrode et al., 2017; Suva et al., 2013).”
Pepin, M. E., Ha, C., Crossman, D. K., Litovsky, S. H., Varambally, S., Barchue, J. P., Pamboukian, S. V., Diakos, N., Drakos, S. G., Pogwizd, S. M., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0104-x · Cited by 130
“While epigenetics was originally used to explain the establishment of cellular identity during embryogenesis, the reverse process occurs in many adult diseases such as cancer [12].”
Bulstrode, H. J. C. J., Johnstone, E. R., Marqués‐Torrejón, M. Á., Ferguson, K. M., Bressan, R. B., Blin, C., Grant, V., Gogolok, S., Gangoso, E., Gagrica, S., et al. (2017) · Genes & Development · doi:10.1101/gad.293027.116 · Cited by 133
Clinical Circulating Tumor DNA Testing for Precision Oncology
Kim, H., & Park, K. U. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1026 · Cited by 135
Metabostemness: A New Cancer Hallmark
Menéndez, J. A., & Alarcón, T. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00262 · Cited by 119
“(1) the cellular metabotype determines the global success of the epitranscriptional reprograming that redirects normal and non-CSC tumor cells toward less-differentiated CSC cellular states; (2) the cellular metabotype imposes the “permitted” and “protected” cellular modes that allow or prevent, respectively, the comp…”
BackgroundUnraveling the journey of cancer stem cells from origin to metastasis
Nimmakayala, R. K., Batra, S. K., & Ponnusamy, M. P. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.006 · Cited by 123
“The combined induction of pluripotent transcription factors POU3F2+SOX2+SALL2+OLIG2 reprogram glioblastoma cells into glioma CSCs [103].”
BackgroundAnnunziata, I., van de Vlekkert, D., Wolf, E., Finkelstein, D., Neale, G., Machado, E., Mosca, R., Campos, Y., Tillman, H., Roussel, M. F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11568-0 · Cited by 115
Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer
Huo, M., Zhang, J., Huang, W., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.793428 · Cited by 126
Metabolism and epigenetics: a link cancer cells exploit
Carrer, A., & Wellen, K. E. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.11.012 · Cited by 109
“At the same time, it is manifest that the epigenome is reorganized in tumor cells, a feature that is now considered an enabling characteristic of cancer[9,10].”
BackgroundCellular Pliancy and the Multistep Process of Tumorigenesis
Puisieux, A., Pommier, R. M., Morel, A., & Lavial, F. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.007 · Cited by 122
“Consistent with this hypothesis, a large number of factors controlling induced pluripotency are known to be genuine oncoproteins (Suvà et al., 2013).”
BackgroundMusashi2 sustains the mixed-lineage leukemia–driven stem cell regulatory program
Park, S.-M., Gönen, M., Vu, L., Minuesa, G., Tivnan, P., Barlowe, T. S., Taggart, J., Lu, Y., Deering, R. P., Hacohen, N., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78440 · Cited by 110
“org Volume 125 Number 3 March 2015 Introduction A dysregulated developmental epigenetic program is considered to be a general feature of many cancers, and mutations or chromosomal translocations with histone methyltransferases contribute to transformation in myeloid leukemias (1, 2).”
Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment
Malla, R. R., Surepalli, N., Farran, B., Malhotra, S. V., & Nagaraju, G. P. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103285 · Cited by 118
Kawamura, N., Nimura, K., Nagano, H., Yamaguchi, S., Nonomura, N., & Kaneda, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4293 · Cited by 93
Chromatin regulation at the frontier of synthetic biology
Keung, A. J., Joung, J. K., Khalil, A. S., & Collins, J. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3900 · Cited by 106
An epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 109
Open Chromatin, Epigenetic Plasticity, and Nuclear Organization in Pluripotency
Schlesinger, S., & Meshorer, E. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.01.003 · Cited by 110
Epigenetic Mechanisms in Cerebral Ischemia
Schweizer, S., Meisel, A., & Märschenz, S. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.93 · Cited by 110
He, X., Yan, B., Liu, S., Jia, J., Lai, W., Xing, X., Tang, C., Luo, D., Tan, T., Jiang, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0268 · Cited by 114
“Chromatin remodeling factors are crucial factors of epigenetics and play a critical part in the development of several malignancies (25, 26), but their role in the progress of NPC remains unknown.”
BackgroundZhu, Z., McGray, A. R., Jiang, W., Lu, B., Kaliński, P., & Guo, Z. S. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01664-z · Cited by 115
“As stated earlier, OVs themselves can modulate the TME and turn cold tumor hot [55, 56].”
BackgroundInfluentialIKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation
Park, S.-M., Cho, H., Thornton, A. M., Barlowe, T. S., Chou, T., Chhangawala, S., Fairchild, L., Taggart, J., Chow, A., Schurer, A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.10.016 · Cited by 97
“This disease is caused by various mutations and chromosomal translocations that target epigenetic regulators (Suva et al., 2013).”
BackgroundEndogenous GABAA receptor activity suppresses glioma growth
Blanchart, A., Fernando, R. N., Häring, M., Assaife‐Lopes, N., Romanov, R. A., Andäng, M., Harkany, T., & Ernfors, P. (2016) · Oncogene · doi:10.1038/onc.2016.245 · Cited by 114
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhang, Z., Ma, P., Jing, Y., Yan, Y., Cai, M.-C., Zhang, M., Zhang, S., Peng, H., Ji, Z.-L., Di, W., et al. (2016) · Theranostics · doi:10.7150/thno.13178 · Cited by 99
“Epigenetic regulators have recently emerged as a new class of therapeutic targets in cancer treatment [13, 14].”
BackgroundSox2 Is Required to Maintain Cancer Stem Cells in a Mouse Model of High-Grade Oligodendroglioma
Favaro, R., Appolloni, I., Pellegatta, S., Sanga, A. B., Pagella, P., Gambini, E., Pisati, F., Ottolenghi, S., Foti, M., Finocchiaro, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1942 · Cited by 100
Metadata
- Authors
- Suvà, M. L., Riggi, N., & Bernstein, B. E.
- Affiliations
- Broad Institute (US)
- Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
- Corresponding author
- Suvà, Mario L.
- Bernstein, Bradley E.
- Venue
- Science
- Published
- 2013-03-29
- Volume
- 339
- Issue
- 6127
- Pages
- 1567-1570
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3821556
- OpenAlex
- W2090757807
- Cited by
- 706
- References
- 64
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 19 · 2023: 40 · 2022: 34 · 2021: 61 · 2020: 62 · 2019: 48 · 2018: 58 · 2017: 72 · 2016: 67 · 2015: 76 · 2014: 85 · 2013: 43
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of Environmental Health Sciences (U01ES017155)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic reprogramming, cancer, induced pluripotency, transcription factors, chromatin regulators, oncogenic transformation, tumor heterogeneity, cancer stem cells, cell state transitions
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Chromatin, Humans, Neoplasms, Transcription Factors, Neoplastic Stem Cells, DNA Methylation, Pluripotent Stem Cells, Epigenesis, Genetic, Mice, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.